(Q38123680)

29 August 2017

title

Luminal breast cancer: from biology to treatment (English)

1 reference

29 August 2017

1 reference

Michail Ignatiadis

1

1 reference

29 August 2017

Christos Sotiriou

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

23 July 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

494-506

1 reference

European cancer mortality predictions for the year 2013.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Outcome of special types of luminal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The molecular portraits of breast tumors are conserved across microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A three-gene model to robustly identify breast cancer molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Mutational processes molding the genomes of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The life history of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The genomic landscape of breast cancer as a therapeutic roadmap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Does tumour dormancy offer a therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Models, mechanisms and clinical evidence for cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Microenvironments dictating tumor cell dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Controversies in clinical cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Biology of breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Effects of bone-targeted agents on cancer progression and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Detection, clinical relevance and specific biological properties of disseminating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Circulating tumour cells in non-metastatic breast cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

CTCs in primary breast cancer (I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Development of PI3K inhibitors: lessons learned from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Emerging targeted agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The retinoblastoma protein and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Evolution of the cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Receptor conversion in distant breast cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Whole-genome sequencing and cancer therapy: is too much ever enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Minimal residual disease and circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Personalized oncology through integrative high-throughput sequencing: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Molecular prescreening to select patient population in early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The landscape of cancer genes and mutational processes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Whole-genome analysis informs breast cancer response to aromatase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Quality of health care delivered to adults in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Bisphosphonates in early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Circulating tumor cells--new challenges ahead

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

HER2 status and benefit from adjuvant trastuzumab in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Genetic Interactions in Cancer Progression and Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Prognosis and gene expression profiling of 20q13-amplified breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Toward molecular imaging-driven drug development in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.124

Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups

31 March 2020

1 reference

12 December 2020

The molecular profile of luminal B breast cancer

1 reference

12 December 2020

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

1 reference

12 December 2020

10.1038/NRCLINONC.2013.124

Identifiers

DOI

1 reference

29 August 2017

1 reference